Sorrento Therapeutics, Inc. (SRNE)
After hours:
| Previous close | 1.5400 |
| Open | 1.5500 |
| Bid | 1.6100 x 45100 |
| Ask | 1.6200 x 1000 |
| Day's range | 1.5039 - 1.6300 |
| 52-week range | 1.1500 - 11.0700 |
| Volume | |
| Avg. volume | 9,485,547 |
| Market cap | 630.092M |
| Beta (5Y monthly) | 2.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5270 |
| Earnings date | 11 May 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.00 |
- Zacks
Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates
Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain.SP-103 is a pharmacologically validated drug candidate and has the potential as a best-in-class agent of pain treatment for low back pain without the limitations of current t
- GlobeNewswire
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento’s board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer m
